SlideShare a Scribd company logo

Funding A Medical Device Startup In The Current Economy

A presentation delivered June 4, 2009 describing the impact of the economic crisis on venture and angel investing and common sense steps for fundraising for Medical Device Startups. No one is an expert now.

1 of 31
Download to read offline
Funding a Medical Device
Startup in the Current Economy
       Michael J. Weickert, PhD
          President and CEO
     S.E.A. Medical Systems, Inc.
    President, Wit Creek Consulting
Who Am I?
• Michael J. Weickert
• PhD Genetics, UW Madison, NIH, NCI
• Biotech Industry since 1992
   – Bay area since 1998; Nektar, CBO StrataGent, CBO Corium
• President and CEO S.E.A. Medical Systems, Inc.
   – Medical device company in Sunnyvale, CA
• President Wit Creek Consulting
   – Business strategy, business plan consultancy
• Member Life Science Angels
   – Member medical device and Bio screening committees
• Start-up Advisor
   – Lypro Biosciences, NanoBioSciences
• Venture Partner Kranenberg Fund
• Limited Partner Quantum Technology Partners
Agenda
• What has the current economy done to
  investing?
  – How bad is it?
• What can a medical device company do to
  raise funds now?
  – Is there any hope?
We have fallen off a cliff: 1Q09 dollars
 down 61%, deals down 45% from 1Q08




Quarterly investment activity was down 47 percent in dollars and 37 percent in
deals from the fourth quarter of 2008 when $5.7 billion was invested in 866 deals.
The quarter, which saw double digit declines in every major industry sector,
marks the lowest venture investment level since 1997.
Q1 2009 US Report; www.pwcmoneytree.com
Steep declines across all industries




The Life Sciences sector (Biotechnology and Medical Devices combined)
experienced a 40 percent decline in terms of dollars and a 31 percent drop in deals
with $989 million going into 133 rounds. Investment in Medical Device investments
fell 27 percent to $412 million.
 Q1 2009 US Report; www.pwcmoneytree.com
Deals down all over the country
      Drop >61% in Silicon Valley




Silicon Valley continued to garner the lion’s share of venture capital dollars,
capturing 39 percent of the $3.0 billion invested in US-based companies
throughout the quarter. The New England Region maintained its customary
number two position despite a 51 percent decline in dollars and a 36 percent
drop in deals from the fourth quarter of 2008.
Q1 2009 US Report; www.pwcmoneytree.com

Recommended

MEDICAL DEVICE DEVELOPMENT_0327
MEDICAL DEVICE DEVELOPMENT_0327MEDICAL DEVICE DEVELOPMENT_0327
MEDICAL DEVICE DEVELOPMENT_0327Robert Stathopulos
 
Medical Product Development cycle
Medical Product Development cycleMedical Product Development cycle
Medical Product Development cyclemax hanafi
 
Shedding Some Light on the Insights Lurking in the PMA Database
Shedding Some Light on the Insights Lurking in the PMA DatabaseShedding Some Light on the Insights Lurking in the PMA Database
Shedding Some Light on the Insights Lurking in the PMA DatabaseRevital (Tali) Hirsch
 
How to Make Postmarket Surveillance More Cost Effective
How to Make Postmarket Surveillance More Cost EffectiveHow to Make Postmarket Surveillance More Cost Effective
How to Make Postmarket Surveillance More Cost EffectiveApril Bright
 
Regulatory strategy for medical device start-ups
Regulatory strategy for medical device start-upsRegulatory strategy for medical device start-ups
Regulatory strategy for medical device start-upsRina Nir
 
Design and development of medical device
Design and development of medical deviceDesign and development of medical device
Design and development of medical deviceMalesh M
 
Med Tech Innovation Clusters
Med Tech Innovation ClustersMed Tech Innovation Clusters
Med Tech Innovation ClustersTim Blair
 

More Related Content

What's hot

What Is It? Product Development vs. Product Management
What Is It? Product Development vs. Product Management What Is It? Product Development vs. Product Management
What Is It? Product Development vs. Product Management April Bright
 
FDA Update and Q&A: UDI
FDA Update and Q&A: UDIFDA Update and Q&A: UDI
FDA Update and Q&A: UDIApril Bright
 
Design for reimbursement in medical device development
Design for reimbursement in medical device developmentDesign for reimbursement in medical device development
Design for reimbursement in medical device developmentAmber Hol Horeman
 
Modernize the Orthopaedic Supply Chain: A Surgeon’s View
Modernize the Orthopaedic Supply Chain: A Surgeon’s ViewModernize the Orthopaedic Supply Chain: A Surgeon’s View
Modernize the Orthopaedic Supply Chain: A Surgeon’s ViewApril Bright
 
Strategies for Device Approval in China, India, South Korea and Australia
Strategies for Device Approval in China, India, South Korea and AustraliaStrategies for Device Approval in China, India, South Korea and Australia
Strategies for Device Approval in China, India, South Korea and AustraliaApril Bright
 
Lean agile feb2017-patca_a_joseph_ss
Lean agile feb2017-patca_a_joseph_ssLean agile feb2017-patca_a_joseph_ss
Lean agile feb2017-patca_a_joseph_ssAaron Joseph
 
Accelerating Medical Device Development While Improving Compliance
Accelerating Medical Device Development While Improving ComplianceAccelerating Medical Device Development While Improving Compliance
Accelerating Medical Device Development While Improving ComplianceAaron Joseph
 
Analyze and Optimize Your Supply Chain Operations for Higher Performance - OM...
Analyze and Optimize Your Supply Chain Operations for Higher Performance - OM...Analyze and Optimize Your Supply Chain Operations for Higher Performance - OM...
Analyze and Optimize Your Supply Chain Operations for Higher Performance - OM...April Bright
 
New European Medical Device Regulations: Keeping Your Orthopaedic and Spine ...
New European Medical Device Regulations:  Keeping Your Orthopaedic and Spine ...New European Medical Device Regulations:  Keeping Your Orthopaedic and Spine ...
New European Medical Device Regulations: Keeping Your Orthopaedic and Spine ...April Bright
 
Medical Device Development Lifecycle
Medical Device Development LifecycleMedical Device Development Lifecycle
Medical Device Development LifecycleTim Blair
 
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...April Bright
 
Orthopaedic Device Industry Business Models: 2020 and Beyond
Orthopaedic Device Industry Business Models: 2020 and BeyondOrthopaedic Device Industry Business Models: 2020 and Beyond
Orthopaedic Device Industry Business Models: 2020 and BeyondApril Bright
 
Additive Manufacturing: Industry Addresses Standards, Quality, Evidence Build...
Additive Manufacturing: Industry Addresses Standards, Quality, Evidence Build...Additive Manufacturing: Industry Addresses Standards, Quality, Evidence Build...
Additive Manufacturing: Industry Addresses Standards, Quality, Evidence Build...April Bright
 
Computational Modeling & Simulation in Orthopedics: Tools to Comply in an Ev...
Computational Modeling & Simulation in Orthopedics:  Tools to Comply in an Ev...Computational Modeling & Simulation in Orthopedics:  Tools to Comply in an Ev...
Computational Modeling & Simulation in Orthopedics: Tools to Comply in an Ev...April Bright
 
CAPA: Using Risk-Based Decision-Making Toward Closure
CAPA: Using Risk-Based Decision-Making Toward ClosureCAPA: Using Risk-Based Decision-Making Toward Closure
CAPA: Using Risk-Based Decision-Making Toward ClosureApril Bright
 
QMS Effectiveness: Tracking and Trending Quality Data - OMTEC 2017
QMS Effectiveness: Tracking and Trending Quality Data - OMTEC 2017QMS Effectiveness: Tracking and Trending Quality Data - OMTEC 2017
QMS Effectiveness: Tracking and Trending Quality Data - OMTEC 2017April Bright
 
UDI: Where Do We Go From Here?
UDI: Where Do We Go From Here?UDI: Where Do We Go From Here?
UDI: Where Do We Go From Here?April Bright
 
Medical Device Development - Concept to Commercialization | Jahnavi Lokre | L...
Medical Device Development - Concept to Commercialization | Jahnavi Lokre | L...Medical Device Development - Concept to Commercialization | Jahnavi Lokre | L...
Medical Device Development - Concept to Commercialization | Jahnavi Lokre | L...UCICove
 
OSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
OSMA: Orthopedic Industry's Top Regulatory Challenges and OpportunitiesOSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
OSMA: Orthopedic Industry's Top Regulatory Challenges and OpportunitiesApril Bright
 
Operations: Top Reasons for Long Lead Times and What to Do About Them
Operations: Top Reasons for Long Lead Times and What to Do About ThemOperations: Top Reasons for Long Lead Times and What to Do About Them
Operations: Top Reasons for Long Lead Times and What to Do About ThemApril Bright
 

What's hot (20)

What Is It? Product Development vs. Product Management
What Is It? Product Development vs. Product Management What Is It? Product Development vs. Product Management
What Is It? Product Development vs. Product Management
 
FDA Update and Q&A: UDI
FDA Update and Q&A: UDIFDA Update and Q&A: UDI
FDA Update and Q&A: UDI
 
Design for reimbursement in medical device development
Design for reimbursement in medical device developmentDesign for reimbursement in medical device development
Design for reimbursement in medical device development
 
Modernize the Orthopaedic Supply Chain: A Surgeon’s View
Modernize the Orthopaedic Supply Chain: A Surgeon’s ViewModernize the Orthopaedic Supply Chain: A Surgeon’s View
Modernize the Orthopaedic Supply Chain: A Surgeon’s View
 
Strategies for Device Approval in China, India, South Korea and Australia
Strategies for Device Approval in China, India, South Korea and AustraliaStrategies for Device Approval in China, India, South Korea and Australia
Strategies for Device Approval in China, India, South Korea and Australia
 
Lean agile feb2017-patca_a_joseph_ss
Lean agile feb2017-patca_a_joseph_ssLean agile feb2017-patca_a_joseph_ss
Lean agile feb2017-patca_a_joseph_ss
 
Accelerating Medical Device Development While Improving Compliance
Accelerating Medical Device Development While Improving ComplianceAccelerating Medical Device Development While Improving Compliance
Accelerating Medical Device Development While Improving Compliance
 
Analyze and Optimize Your Supply Chain Operations for Higher Performance - OM...
Analyze and Optimize Your Supply Chain Operations for Higher Performance - OM...Analyze and Optimize Your Supply Chain Operations for Higher Performance - OM...
Analyze and Optimize Your Supply Chain Operations for Higher Performance - OM...
 
New European Medical Device Regulations: Keeping Your Orthopaedic and Spine ...
New European Medical Device Regulations:  Keeping Your Orthopaedic and Spine ...New European Medical Device Regulations:  Keeping Your Orthopaedic and Spine ...
New European Medical Device Regulations: Keeping Your Orthopaedic and Spine ...
 
Medical Device Development Lifecycle
Medical Device Development LifecycleMedical Device Development Lifecycle
Medical Device Development Lifecycle
 
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...
FDA Inspections are Different from ISO Audits, So Don't Treat Them the Same -...
 
Orthopaedic Device Industry Business Models: 2020 and Beyond
Orthopaedic Device Industry Business Models: 2020 and BeyondOrthopaedic Device Industry Business Models: 2020 and Beyond
Orthopaedic Device Industry Business Models: 2020 and Beyond
 
Additive Manufacturing: Industry Addresses Standards, Quality, Evidence Build...
Additive Manufacturing: Industry Addresses Standards, Quality, Evidence Build...Additive Manufacturing: Industry Addresses Standards, Quality, Evidence Build...
Additive Manufacturing: Industry Addresses Standards, Quality, Evidence Build...
 
Computational Modeling & Simulation in Orthopedics: Tools to Comply in an Ev...
Computational Modeling & Simulation in Orthopedics:  Tools to Comply in an Ev...Computational Modeling & Simulation in Orthopedics:  Tools to Comply in an Ev...
Computational Modeling & Simulation in Orthopedics: Tools to Comply in an Ev...
 
CAPA: Using Risk-Based Decision-Making Toward Closure
CAPA: Using Risk-Based Decision-Making Toward ClosureCAPA: Using Risk-Based Decision-Making Toward Closure
CAPA: Using Risk-Based Decision-Making Toward Closure
 
QMS Effectiveness: Tracking and Trending Quality Data - OMTEC 2017
QMS Effectiveness: Tracking and Trending Quality Data - OMTEC 2017QMS Effectiveness: Tracking and Trending Quality Data - OMTEC 2017
QMS Effectiveness: Tracking and Trending Quality Data - OMTEC 2017
 
UDI: Where Do We Go From Here?
UDI: Where Do We Go From Here?UDI: Where Do We Go From Here?
UDI: Where Do We Go From Here?
 
Medical Device Development - Concept to Commercialization | Jahnavi Lokre | L...
Medical Device Development - Concept to Commercialization | Jahnavi Lokre | L...Medical Device Development - Concept to Commercialization | Jahnavi Lokre | L...
Medical Device Development - Concept to Commercialization | Jahnavi Lokre | L...
 
OSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
OSMA: Orthopedic Industry's Top Regulatory Challenges and OpportunitiesOSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
OSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
 
Operations: Top Reasons for Long Lead Times and What to Do About Them
Operations: Top Reasons for Long Lead Times and What to Do About ThemOperations: Top Reasons for Long Lead Times and What to Do About Them
Operations: Top Reasons for Long Lead Times and What to Do About Them
 

Viewers also liked

Is your medical device idea viable?
Is your medical device idea viable?Is your medical device idea viable?
Is your medical device idea viable?Carl Lincoln
 
BIC101 Acceleration Program
BIC101 Acceleration ProgramBIC101 Acceleration Program
BIC101 Acceleration Programbicangels
 
Medical entrepreneurship
Medical entrepreneurshipMedical entrepreneurship
Medical entrepreneurshipJorge Saguinsin
 
Medical Device Reimbursement Process
Medical Device Reimbursement ProcessMedical Device Reimbursement Process
Medical Device Reimbursement ProcessAmir Inbar
 
"Stan Lapidus: Profile of a Medical Entrepreneur."
"Stan Lapidus: Profile of a Medical Entrepreneur.""Stan Lapidus: Profile of a Medical Entrepreneur."
"Stan Lapidus: Profile of a Medical Entrepreneur."Paulo Martins
 
Girişimci Yatırımcı Sunumundan Ne Bekler?
Girişimci Yatırımcı Sunumundan Ne Bekler?Girişimci Yatırımcı Sunumundan Ne Bekler?
Girişimci Yatırımcı Sunumundan Ne Bekler?bicangels
 
Startnowhow 20.10.16 Entrepreneurship as a Profession
Startnowhow 20.10.16 Entrepreneurship as a ProfessionStartnowhow 20.10.16 Entrepreneurship as a Profession
Startnowhow 20.10.16 Entrepreneurship as a Professionbicangels
 
Medical Device Development - Trends, Challenges and Risks
Medical Device Development - Trends, Challenges and RisksMedical Device Development - Trends, Challenges and Risks
Medical Device Development - Trends, Challenges and RisksDina Sifri
 
Kolay Randevu - BIC 101
Kolay Randevu - BIC 101 Kolay Randevu - BIC 101
Kolay Randevu - BIC 101 bicangels
 
Business Incubator Blueprint: How to Open a Business Incubator and Maximize R...
Business Incubator Blueprint: How to Open a Business Incubator and Maximize R...Business Incubator Blueprint: How to Open a Business Incubator and Maximize R...
Business Incubator Blueprint: How to Open a Business Incubator and Maximize R...Center For Entrepreneurial Innovation
 
Attracting and Maintaining Institutional Investment: Solar PV
Attracting and Maintaining Institutional Investment: Solar PVAttracting and Maintaining Institutional Investment: Solar PV
Attracting and Maintaining Institutional Investment: Solar PVEversheds Sutherland
 
Yatırımcı Sunumu Hazırlama
Yatırımcı Sunumu HazırlamaYatırımcı Sunumu Hazırlama
Yatırımcı Sunumu HazırlamaTaylan Demirkaya
 
Design control FDA requirements
Design control FDA requirementsDesign control FDA requirements
Design control FDA requirementsLatvian University
 
Medical device development lifecycle
Medical device development lifecycleMedical device development lifecycle
Medical device development lifecycleTim Blair
 
Medical device industry 2014 - A Healthcare Sector Analysis
Medical device industry 2014 - A Healthcare Sector AnalysisMedical device industry 2014 - A Healthcare Sector Analysis
Medical device industry 2014 - A Healthcare Sector AnalysisVikas Soni
 
Private Equity and Venture Capital
Private Equity and Venture CapitalPrivate Equity and Venture Capital
Private Equity and Venture CapitalAlexey Milevskiy
 

Viewers also liked (17)

Is your medical device idea viable?
Is your medical device idea viable?Is your medical device idea viable?
Is your medical device idea viable?
 
BIC101 Acceleration Program
BIC101 Acceleration ProgramBIC101 Acceleration Program
BIC101 Acceleration Program
 
Medical entrepreneurship
Medical entrepreneurshipMedical entrepreneurship
Medical entrepreneurship
 
Medical Device Reimbursement Process
Medical Device Reimbursement ProcessMedical Device Reimbursement Process
Medical Device Reimbursement Process
 
"Stan Lapidus: Profile of a Medical Entrepreneur."
"Stan Lapidus: Profile of a Medical Entrepreneur.""Stan Lapidus: Profile of a Medical Entrepreneur."
"Stan Lapidus: Profile of a Medical Entrepreneur."
 
Swaps
SwapsSwaps
Swaps
 
Girişimci Yatırımcı Sunumundan Ne Bekler?
Girişimci Yatırımcı Sunumundan Ne Bekler?Girişimci Yatırımcı Sunumundan Ne Bekler?
Girişimci Yatırımcı Sunumundan Ne Bekler?
 
Startnowhow 20.10.16 Entrepreneurship as a Profession
Startnowhow 20.10.16 Entrepreneurship as a ProfessionStartnowhow 20.10.16 Entrepreneurship as a Profession
Startnowhow 20.10.16 Entrepreneurship as a Profession
 
Medical Device Development - Trends, Challenges and Risks
Medical Device Development - Trends, Challenges and RisksMedical Device Development - Trends, Challenges and Risks
Medical Device Development - Trends, Challenges and Risks
 
Kolay Randevu - BIC 101
Kolay Randevu - BIC 101 Kolay Randevu - BIC 101
Kolay Randevu - BIC 101
 
Business Incubator Blueprint: How to Open a Business Incubator and Maximize R...
Business Incubator Blueprint: How to Open a Business Incubator and Maximize R...Business Incubator Blueprint: How to Open a Business Incubator and Maximize R...
Business Incubator Blueprint: How to Open a Business Incubator and Maximize R...
 
Attracting and Maintaining Institutional Investment: Solar PV
Attracting and Maintaining Institutional Investment: Solar PVAttracting and Maintaining Institutional Investment: Solar PV
Attracting and Maintaining Institutional Investment: Solar PV
 
Yatırımcı Sunumu Hazırlama
Yatırımcı Sunumu HazırlamaYatırımcı Sunumu Hazırlama
Yatırımcı Sunumu Hazırlama
 
Design control FDA requirements
Design control FDA requirementsDesign control FDA requirements
Design control FDA requirements
 
Medical device development lifecycle
Medical device development lifecycleMedical device development lifecycle
Medical device development lifecycle
 
Medical device industry 2014 - A Healthcare Sector Analysis
Medical device industry 2014 - A Healthcare Sector AnalysisMedical device industry 2014 - A Healthcare Sector Analysis
Medical device industry 2014 - A Healthcare Sector Analysis
 
Private Equity and Venture Capital
Private Equity and Venture CapitalPrivate Equity and Venture Capital
Private Equity and Venture Capital
 

Similar to Funding A Medical Device Startup In The Current Economy

Venture Capital Investing Maintains Steady Pace in Q3 2003
Venture Capital Investing Maintains Steady Pace in Q3 2003Venture Capital Investing Maintains Steady Pace in Q3 2003
Venture Capital Investing Maintains Steady Pace in Q3 2003mensa25
 
Dimension Mill Annual Presentation
Dimension Mill Annual PresentationDimension Mill Annual Presentation
Dimension Mill Annual PresentationDimension Mill
 
Venture Investment - Q1-05
Venture Investment - Q1-05 Venture Investment - Q1-05
Venture Investment - Q1-05 mensa25
 
Finance And Business Planning
Finance And Business PlanningFinance And Business Planning
Finance And Business PlanningOlesea FORTUNA
 
Finance And Business Planning
Finance And Business PlanningFinance And Business Planning
Finance And Business PlanningOlesea FORTUNA
 
Thefundedsick 1226521688868759-8
Thefundedsick 1226521688868759-8Thefundedsick 1226521688868759-8
Thefundedsick 1226521688868759-8Jose Gonzalez
 
Angel & Venture Capital Finance: Where is the Money Moving?
Angel & Venture Capital Finance: Where is the Money Moving?Angel & Venture Capital Finance: Where is the Money Moving?
Angel & Venture Capital Finance: Where is the Money Moving?dbeisel
 
Becoming an Angel Investor
Becoming an Angel InvestorBecoming an Angel Investor
Becoming an Angel InvestorElaine Werffeli
 
Life Sciences Regain Prominence in Venture Capital Arena
 	Life Sciences Regain Prominence in Venture Capital Arena 	Life Sciences Regain Prominence in Venture Capital Arena
Life Sciences Regain Prominence in Venture Capital Arenamensa25
 
Angel investing 101: An Introduction to Angel Investing Aug 2019 SS
Angel investing 101: An Introduction to Angel Investing Aug 2019 SSAngel investing 101: An Introduction to Angel Investing Aug 2019 SS
Angel investing 101: An Introduction to Angel Investing Aug 2019 SSElaine Werffeli
 
Corporate VC Gains Strength
 	Corporate VC Gains Strength   	Corporate VC Gains Strength
Corporate VC Gains Strength mensa25
 
A Study On Private Equity Investments
A Study On Private Equity InvestmentsA Study On Private Equity Investments
A Study On Private Equity InvestmentsMichelle Love
 
DealMarket Digest Issue86 - 8th March 2013
DealMarket Digest Issue86 - 8th March 2013DealMarket Digest Issue86 - 8th March 2013
DealMarket Digest Issue86 - 8th March 2013Urs Haeusler
 
Venture Investment Q3 ‘04
Venture Investment Q3 ‘04Venture Investment Q3 ‘04
Venture Investment Q3 ‘04mensa25
 
Venture Capital Investment Q4 04 – MoneyTree Survey
Venture Capital Investment Q4 04 – MoneyTree Survey Venture Capital Investment Q4 04 – MoneyTree Survey
Venture Capital Investment Q4 04 – MoneyTree Survey mensa25
 
Angel Group Investing Heats Up: Q1 2014 Halo Report
Angel Group Investing Heats Up: Q1 2014 Halo Report Angel Group Investing Heats Up: Q1 2014 Halo Report
Angel Group Investing Heats Up: Q1 2014 Halo Report sdickey
 
VC Investments Q2 ’06 - MoneyTree
  	VC Investments Q2 ’06 - MoneyTree    	VC Investments Q2 ’06 - MoneyTree
VC Investments Q2 ’06 - MoneyTree mensa25
 

Similar to Funding A Medical Device Startup In The Current Economy (20)

Venture Capital Investing Maintains Steady Pace in Q3 2003
Venture Capital Investing Maintains Steady Pace in Q3 2003Venture Capital Investing Maintains Steady Pace in Q3 2003
Venture Capital Investing Maintains Steady Pace in Q3 2003
 
Dimension Mill Annual Presentation
Dimension Mill Annual PresentationDimension Mill Annual Presentation
Dimension Mill Annual Presentation
 
Venture Investment - Q1-05
Venture Investment - Q1-05 Venture Investment - Q1-05
Venture Investment - Q1-05
 
Finance And Business Planning
Finance And Business PlanningFinance And Business Planning
Finance And Business Planning
 
Finance And Business Planning
Finance And Business PlanningFinance And Business Planning
Finance And Business Planning
 
Thefundedsick 1226521688868759-8
Thefundedsick 1226521688868759-8Thefundedsick 1226521688868759-8
Thefundedsick 1226521688868759-8
 
Angel & Venture Capital Finance: Where is the Money Moving?
Angel & Venture Capital Finance: Where is the Money Moving?Angel & Venture Capital Finance: Where is the Money Moving?
Angel & Venture Capital Finance: Where is the Money Moving?
 
Becoming an Angel Investor
Becoming an Angel InvestorBecoming an Angel Investor
Becoming an Angel Investor
 
Life Sciences Regain Prominence in Venture Capital Arena
 	Life Sciences Regain Prominence in Venture Capital Arena 	Life Sciences Regain Prominence in Venture Capital Arena
Life Sciences Regain Prominence in Venture Capital Arena
 
Angel investing 101: An Introduction to Angel Investing Aug 2019 SS
Angel investing 101: An Introduction to Angel Investing Aug 2019 SSAngel investing 101: An Introduction to Angel Investing Aug 2019 SS
Angel investing 101: An Introduction to Angel Investing Aug 2019 SS
 
Corporate VC Gains Strength
 	Corporate VC Gains Strength   	Corporate VC Gains Strength
Corporate VC Gains Strength
 
A Study On Private Equity Investments
A Study On Private Equity InvestmentsA Study On Private Equity Investments
A Study On Private Equity Investments
 
DealMarket Digest Issue86 - 8th March 2013
DealMarket Digest Issue86 - 8th March 2013DealMarket Digest Issue86 - 8th March 2013
DealMarket Digest Issue86 - 8th March 2013
 
Start Fund Q2 2009
Start Fund Q2 2009Start Fund Q2 2009
Start Fund Q2 2009
 
Venture Investment Q3 ‘04
Venture Investment Q3 ‘04Venture Investment Q3 ‘04
Venture Investment Q3 ‘04
 
Venture Capital Investment Q4 04 – MoneyTree Survey
Venture Capital Investment Q4 04 – MoneyTree Survey Venture Capital Investment Q4 04 – MoneyTree Survey
Venture Capital Investment Q4 04 – MoneyTree Survey
 
Halo Report Q1 2014
Halo Report Q1 2014 Halo Report Q1 2014
Halo Report Q1 2014
 
Angel Group Investing Heats Up: Q1 2014 Halo Report
Angel Group Investing Heats Up: Q1 2014 Halo Report Angel Group Investing Heats Up: Q1 2014 Halo Report
Angel Group Investing Heats Up: Q1 2014 Halo Report
 
SWVL last version2.pptx
SWVL last version2.pptxSWVL last version2.pptx
SWVL last version2.pptx
 
VC Investments Q2 ’06 - MoneyTree
  	VC Investments Q2 ’06 - MoneyTree    	VC Investments Q2 ’06 - MoneyTree
VC Investments Q2 ’06 - MoneyTree
 

Recently uploaded

Introducing Herringbone Collection by Surya Click
Introducing Herringbone Collection by Surya ClickIntroducing Herringbone Collection by Surya Click
Introducing Herringbone Collection by Surya ClickSurya Panel Private Limited
 
Actionable Fundraising Planning - Slide Presentation.pptx.pdf
Actionable Fundraising Planning - Slide Presentation.pptx.pdfActionable Fundraising Planning - Slide Presentation.pptx.pdf
Actionable Fundraising Planning - Slide Presentation.pptx.pdfBloomerang
 
BeMetals Presentation_February_15_2024.pdf
BeMetals Presentation_February_15_2024.pdfBeMetals Presentation_February_15_2024.pdf
BeMetals Presentation_February_15_2024.pdfDerekIwanaka1
 
FICCI Monthly Bulletin February 2024.pdf
FICCI  Monthly Bulletin February 2024.pdfFICCI  Monthly Bulletin February 2024.pdf
FICCI Monthly Bulletin February 2024.pdfsubarnamostafa1
 
SYY CAGNY 2024 PRESENTATION (February 20, 2024)
SYY CAGNY 2024 PRESENTATION (February 20, 2024)SYY CAGNY 2024 PRESENTATION (February 20, 2024)
SYY CAGNY 2024 PRESENTATION (February 20, 2024)SYYIR
 
Zero Budget Marketing Strategy with KPIs for a Cleaning Detergent Training ...
Zero Budget Marketing  Strategy with KPIs for a Cleaning Detergent  Training ...Zero Budget Marketing  Strategy with KPIs for a Cleaning Detergent  Training ...
Zero Budget Marketing Strategy with KPIs for a Cleaning Detergent Training ...Precious Mvulane CA (SA),RA
 
Kraft Heinz Presentation at the 2024 CAGNY.pdf
Kraft Heinz Presentation at the 2024 CAGNY.pdfKraft Heinz Presentation at the 2024 CAGNY.pdf
Kraft Heinz Presentation at the 2024 CAGNY.pdfNeil Kimberley
 
SD-WAN_MoD.pptx for SD WAN networks connectivity
SD-WAN_MoD.pptx for SD WAN networks connectivitySD-WAN_MoD.pptx for SD WAN networks connectivity
SD-WAN_MoD.pptx for SD WAN networks connectivitybayusch
 
ZEOTAR EV Prince Team English Presentation
ZEOTAR EV Prince Team English PresentationZEOTAR EV Prince Team English Presentation
ZEOTAR EV Prince Team English PresentationKings Reddys
 
edition features a handful of the Brands Of Honour- 2024.pdf
edition features a handful of the Brands Of Honour- 2024.pdfedition features a handful of the Brands Of Honour- 2024.pdf
edition features a handful of the Brands Of Honour- 2024.pdfinsightssuccess2
 
Grevault battery storage system manufacturer
Grevault battery storage system manufacturerGrevault battery storage system manufacturer
Grevault battery storage system manufacturerGrevault
 
Let’s get moving! Setting some goals Optimizing your workflow
Let’s get moving! Setting some goals Optimizing your workflowLet’s get moving! Setting some goals Optimizing your workflow
Let’s get moving! Setting some goals Optimizing your workflowngothuyanct
 
SlideEgg_300445-Apple Inc(1).pptx case study
SlideEgg_300445-Apple Inc(1).pptx case studySlideEgg_300445-Apple Inc(1).pptx case study
SlideEgg_300445-Apple Inc(1).pptx case studyindobanglatradeinter
 
How do hotel linen suppliers contribute to sustainable and eco-friendly pract...
How do hotel linen suppliers contribute to sustainable and eco-friendly pract...How do hotel linen suppliers contribute to sustainable and eco-friendly pract...
How do hotel linen suppliers contribute to sustainable and eco-friendly pract...indhumathi546580
 
Clean/Renewable Energy Virtual Investor Conference
Clean/Renewable Energy Virtual Investor ConferenceClean/Renewable Energy Virtual Investor Conference
Clean/Renewable Energy Virtual Investor ConferenceMarketing847413
 
Diageo Strategy Presentation made in February 2024 CAGNY
Diageo Strategy Presentation made in February 2024 CAGNYDiageo Strategy Presentation made in February 2024 CAGNY
Diageo Strategy Presentation made in February 2024 CAGNYNeil Kimberley
 

Recently uploaded (20)

Polyene General Industries Private Limited
Polyene General Industries Private LimitedPolyene General Industries Private Limited
Polyene General Industries Private Limited
 
Introducing Herringbone Collection by Surya Click
Introducing Herringbone Collection by Surya ClickIntroducing Herringbone Collection by Surya Click
Introducing Herringbone Collection by Surya Click
 
Actionable Fundraising Planning - Slide Presentation.pptx.pdf
Actionable Fundraising Planning - Slide Presentation.pptx.pdfActionable Fundraising Planning - Slide Presentation.pptx.pdf
Actionable Fundraising Planning - Slide Presentation.pptx.pdf
 
BeMetals Presentation_February_15_2024.pdf
BeMetals Presentation_February_15_2024.pdfBeMetals Presentation_February_15_2024.pdf
BeMetals Presentation_February_15_2024.pdf
 
FICCI Monthly Bulletin February 2024.pdf
FICCI  Monthly Bulletin February 2024.pdfFICCI  Monthly Bulletin February 2024.pdf
FICCI Monthly Bulletin February 2024.pdf
 
Pan Dhoni - Modernizing Data And Analytics using AI.pdf
Pan Dhoni - Modernizing Data And Analytics using AI.pdfPan Dhoni - Modernizing Data And Analytics using AI.pdf
Pan Dhoni - Modernizing Data And Analytics using AI.pdf
 
SYY CAGNY 2024 PRESENTATION (February 20, 2024)
SYY CAGNY 2024 PRESENTATION (February 20, 2024)SYY CAGNY 2024 PRESENTATION (February 20, 2024)
SYY CAGNY 2024 PRESENTATION (February 20, 2024)
 
Zero Budget Marketing Strategy with KPIs for a Cleaning Detergent Training ...
Zero Budget Marketing  Strategy with KPIs for a Cleaning Detergent  Training ...Zero Budget Marketing  Strategy with KPIs for a Cleaning Detergent  Training ...
Zero Budget Marketing Strategy with KPIs for a Cleaning Detergent Training ...
 
Kraft Heinz Presentation at the 2024 CAGNY.pdf
Kraft Heinz Presentation at the 2024 CAGNY.pdfKraft Heinz Presentation at the 2024 CAGNY.pdf
Kraft Heinz Presentation at the 2024 CAGNY.pdf
 
SD-WAN_MoD.pptx for SD WAN networks connectivity
SD-WAN_MoD.pptx for SD WAN networks connectivitySD-WAN_MoD.pptx for SD WAN networks connectivity
SD-WAN_MoD.pptx for SD WAN networks connectivity
 
Bryan_Cassady - AI Powered Innovation.pdf
Bryan_Cassady - AI Powered Innovation.pdfBryan_Cassady - AI Powered Innovation.pdf
Bryan_Cassady - AI Powered Innovation.pdf
 
ZEOTAR EV Prince Team English Presentation
ZEOTAR EV Prince Team English PresentationZEOTAR EV Prince Team English Presentation
ZEOTAR EV Prince Team English Presentation
 
edition features a handful of the Brands Of Honour- 2024.pdf
edition features a handful of the Brands Of Honour- 2024.pdfedition features a handful of the Brands Of Honour- 2024.pdf
edition features a handful of the Brands Of Honour- 2024.pdf
 
Grevault battery storage system manufacturer
Grevault battery storage system manufacturerGrevault battery storage system manufacturer
Grevault battery storage system manufacturer
 
Let’s get moving! Setting some goals Optimizing your workflow
Let’s get moving! Setting some goals Optimizing your workflowLet’s get moving! Setting some goals Optimizing your workflow
Let’s get moving! Setting some goals Optimizing your workflow
 
SlideEgg_300445-Apple Inc(1).pptx case study
SlideEgg_300445-Apple Inc(1).pptx case studySlideEgg_300445-Apple Inc(1).pptx case study
SlideEgg_300445-Apple Inc(1).pptx case study
 
How do hotel linen suppliers contribute to sustainable and eco-friendly pract...
How do hotel linen suppliers contribute to sustainable and eco-friendly pract...How do hotel linen suppliers contribute to sustainable and eco-friendly pract...
How do hotel linen suppliers contribute to sustainable and eco-friendly pract...
 
5 Dr. Natalie Petouhoff_AI + Empathy.pdf
5 Dr. Natalie Petouhoff_AI + Empathy.pdf5 Dr. Natalie Petouhoff_AI + Empathy.pdf
5 Dr. Natalie Petouhoff_AI + Empathy.pdf
 
Clean/Renewable Energy Virtual Investor Conference
Clean/Renewable Energy Virtual Investor ConferenceClean/Renewable Energy Virtual Investor Conference
Clean/Renewable Energy Virtual Investor Conference
 
Diageo Strategy Presentation made in February 2024 CAGNY
Diageo Strategy Presentation made in February 2024 CAGNYDiageo Strategy Presentation made in February 2024 CAGNY
Diageo Strategy Presentation made in February 2024 CAGNY
 

Funding A Medical Device Startup In The Current Economy

  • 1. Funding a Medical Device Startup in the Current Economy Michael J. Weickert, PhD President and CEO S.E.A. Medical Systems, Inc. President, Wit Creek Consulting
  • 2. Who Am I? • Michael J. Weickert • PhD Genetics, UW Madison, NIH, NCI • Biotech Industry since 1992 – Bay area since 1998; Nektar, CBO StrataGent, CBO Corium • President and CEO S.E.A. Medical Systems, Inc. – Medical device company in Sunnyvale, CA • President Wit Creek Consulting – Business strategy, business plan consultancy • Member Life Science Angels – Member medical device and Bio screening committees • Start-up Advisor – Lypro Biosciences, NanoBioSciences • Venture Partner Kranenberg Fund • Limited Partner Quantum Technology Partners
  • 3. Agenda • What has the current economy done to investing? – How bad is it? • What can a medical device company do to raise funds now? – Is there any hope?
  • 4. We have fallen off a cliff: 1Q09 dollars down 61%, deals down 45% from 1Q08 Quarterly investment activity was down 47 percent in dollars and 37 percent in deals from the fourth quarter of 2008 when $5.7 billion was invested in 866 deals. The quarter, which saw double digit declines in every major industry sector, marks the lowest venture investment level since 1997. Q1 2009 US Report; www.pwcmoneytree.com
  • 5. Steep declines across all industries The Life Sciences sector (Biotechnology and Medical Devices combined) experienced a 40 percent decline in terms of dollars and a 31 percent drop in deals with $989 million going into 133 rounds. Investment in Medical Device investments fell 27 percent to $412 million. Q1 2009 US Report; www.pwcmoneytree.com
  • 6. Deals down all over the country Drop >61% in Silicon Valley Silicon Valley continued to garner the lion’s share of venture capital dollars, capturing 39 percent of the $3.0 billion invested in US-based companies throughout the quarter. The New England Region maintained its customary number two position despite a 51 percent decline in dollars and a 36 percent drop in deals from the fourth quarter of 2008. Q1 2009 US Report; www.pwcmoneytree.com
  • 7. Venture-backed IPOs disappeared and M&A activity declined
  • 8. Not the best of times • IPO mkt weak – 6 VC backed IPO’s in US in ’08, lowest since 1977, raised $0.5B vs $10.3B in ‘07 – 0 VC backed IPO’s in Q2’08 & Q4’08 – 1 VC backed IPO in Q3’08 – 28 IPO’s in China • 2002-08: 19,300 companies received funding, 351 IPO’s • Time to IPO: ’01 ’02 ’03 ’04 ’05 ’06 ’07 ’08 • # Years from Series A: 4.5 3.3 5.7 5.7 5.6 6.2 7.1 8.3 • M&A weak – 260 deals (down 27%), $13.9B (down 51%) in ’08 vs. ‘07 – 40% drop in ’08 to $300B – 32 deals >$1B in ’08 vs 80 in ‘07 – Median M&A about $80M Q4 2008 US Report; www.pwcmoneytree.com
  • 9. Summary/Facts/Predictions • VC’s stop funding many portfolio companies • More layoffs/cost cutting, unemployment up • New Deals must be perfect • All Deals Series A, lots of down rounds • Fewer Deals per fund, higher reserves • VC syndicate quality more important • VC’s fear capital calls produce LP defaults • VC Fundraising problematic • More Government regulation Q4 2008 US Report; www.pwcmoneytree.com
  • 11. Sequoia recommends SURVIVAL Sequoia Capital Oct 2008
  • 12. What can a medical device company do to raise funds now? First things first • Are you ready to raise funds? • Are you incorporated? • Have you set your equity (stock) pool? • Do you have a business plan? • Do you have a budget to key milestones? • Do you have your complete team?
  • 13. What can a medical device company do to raise funds now? • Friends and Family $1-300k • Grants $100k->1M • Angels $300k->1M • Venture Capital Firms $1M->20M • Strategic Partners $200k->20M • Product Sales ??
  • 14. Friends and Family $1-300k • Investors (even Angels) expect you to raise $200-500k from friends and family before seeking professional investment • Lowers risk – Fund early, often riskiest milestones – Shows people are willing to trust you with their money
  • 15. How do you raise friends and family funds? • Most should qualify as “Accredited Investor” • Treat as professional investors – Provide Business Plan, presentation, prospectus, investment contract • Investment is opportunity for people to participate in an exciting company with tremendous growth potential – If you don’t believe this, don’t ask ANYONE to invest
  • 16. Type of Friends and Family Investments • Priced round – Equity (stock) sold at set price – investors receive a percentage of the company – Pros: investors like clear stake in the company – Cons: sets price that can be difficult to increase in subsequent investment rounds • Convertible debt – Investors loan money which can be converted into equity at the first professional venture round, often at a discount – Pros: professional investor(s) set the price – Cons: cash is owed to the investors if no equity conversion takes place
  • 17. SBIR, STTR Grants $100k->1M • SBIR (Small Business Innovative Research) is a federal set-aside program aimed at supporting R&D in US owned small businesses (companies with less than 500 employees) – Success rate on first time SBIR Phase I grants ~15% • NIH and NSF are among 10 federal agencies which set aside 2.5% of the total funds they award for research grants to be distributed through SBIR/STTR • NIH solicitations are published on its website and are used to support research in a well defined scientific area and/or in a high priority program. – In 2003 more than 80% of the awards allocated were unsolicited (investor-initiated research grants). The investigator initiates the research and submits a grant application within an area that is relevant to the NIH – http://grants.nih.gov/grants/guide/index.html
  • 18. Top 10 recipients of NIH SBIR and STTR Funds in fiscal year 2007 (millions of dollars)
  • 19. Angel Investors $300k->1M • “Accredited Investors” who provides capital for a business start-up • Some angel investors organize into angel groups or angel networks to share research and pool their investment capital • Angel investment accounts in total for almost as much money invested annually as all venture capital funds combined, but into more than ten times as many companies (US$26 billion vs. $30.69 billion in the US in 2007, into 57,000 companies vs. 3,918 companies). • Average angel funding in 2007, ~$450k. Range from a few thousand, to a few million dollars.
  • 20. Angel funding is down too • Angel investing dollars dropped by 26.2 percent last year ($19.2 billion vs. $26 billion in 2007) • Entrepreneurs receiving funding was relatively unchanged from 2007 (55,480 entrepreneurs last year vs 57,120 in 2007) • Angel investment 2008 sectors: – Healthcare-related businesses = 16% – Software = 13% – Retail = 12% – Biotech ventures = 11% – Energy = 8% – Media = 7% 2008 Angel Market Analysis by the Center for Venture Research at the University of New Hampshire
  • 21. Angelsoft* deal funnel from last 12 months 21112 Submitted 1718 In Screening 1185 Invited to Present 679 In Due Diligence 444 Invested Only a small number of companies who apply get funded. This chart shows how many make it through the different stages of the Angel Group process, based on data from our most active groups. *As the exclusive deal management tool to 451 angel groups and VCs and 17,551 investors, Angelsoft processes over 3,200 funding applications a month. This live access to investment data allows us to report trends in the early stage investment market.
  • 22. Venture Capital • Provide private equity capital typically to early- stage, high-potential, growth companies • Generate a return through an eventual realization event such as an IPO or trade sale (M&A) of the company • Venture capital investments generally made as cash in exchange for shares in the invested company • Venture capital investors invest primarily in companies in high technology industries such as biotechnology and ICT – VCs fund ~2% of companies they review
  • 23. Even now some VCs are investing: most active venture investors 1Q2009 Q1 2009 US Report; www.pwcmoneytree.com
  • 27. Strategic Partners Who has… • Expertise to develop your product • Markets similar/related/complimentary product(s) to the same customer(s) • Competes with a product inferior to yours • Has aspirations to sell to the same customers you are targeting • Might be a potential acquirer of your company/product(s)
  • 28. Engaging Strategic Partners • Technology conferences for related industry scientists • Partnering conferences for medical devices • High level introductions to strategic partner management • Contract Business Development professional
  • 29. Strategic partnership models • Support for technology/product development • Feasibility = modest cash for Proof-of-principle demonstration ($100k-1M) • Option = first right of refusal for license/acquisition of technology/product ($100k-2M, may include equity purchase) • Partnership = development support for defined product/technology effort (≥$500k up front, development costs, milestones, royalties, may include equity purchase) • Structured buy-out = pre-priced acquisition in which shareholders receive cash when pre-agreed milestones are achieved
  • 30. Reasons for optimism for medical device companies • Medical device is a strong industry in California and the bay area • Less affected by downturn than other biotechnology - viewed as: – More conservative investment than drug development – More capital efficient
  • 31. Michael J. Weickert, PhD President and CEO S.E.A. Medical Systems, Inc. President, Wit Creek Consulting www.seamedical.com www.witcreek.net mweickert@gmail.com 650-218-1840